Samsung Biologics inks development partnership with Dinona for potential COVID-19 treatment

Samsung Biologics (207940.KS) has entered into a partnership agreement with biotech Dinona, further expanding its CDO capabilities to provide a full scope of its development services from cell line development, process development, to non-clinical and clinical material manufacturing. Under this agreement, Samsung and Dinona will collaborate for fast-track development of DNP-019, a potential COVID-19 antibody therapy.

Since its inception, the Samsung Biologics CDO business has been growing at a rapid pace with near 60 contracts signed in just two years. The business segment continues to expand its market reach through a cumulative track record of various biologics products beyond monoclonal antibodies and by targeting diverse treatment areas including cancer, neurodegenerative diseases, and as with this partnership, COVID-19 treatment.

Samsung Biologics has also recently introduced its proprietary cell-line technology, S-CHOice, this year showing improved titers up to two-fold from the industry average and maintaining over 90% cell viability. With a customized development strategy, Samsung Biologics has showcased a record of achievements in recent years. The company has dramatically reduced the time required for the development stage, taking six months to clinical material manufacturing and seven months to DP release.

Tae Han Kim, CEO Samsung Biologics Said: "Samsung Biologics is always committed to providing the highest quality services to our clients globally to help biotech companies like Dinona focus on their core business, which is drug discovery, As with all our partnerships, we will closely collaborate with our client Dinona to provide the highest client satisfaction and support in its endeavor to bring a potential COVID-19 treatment to market faster and better."

SOURCE Samsung Biologics

Related Posts

Subscribe Our Newsletter